Suppr超能文献

设计、合成及新型 3-蒈烯衍生强效 TDP1 抑制剂的生物学研究。

Design, Synthesis, and Biological Investigation of Novel Classes of 3-Carene-Derived Potent Inhibitors of TDP1.

机构信息

N.N. Vorozhtsov Novosibirsk Institute of Organic Chemistry, Siberian Branch of the Russian Academy of Sciences, 9, Lavrentiev Ave., 630090 Novosibirsk, Russia.

Institute of Chemical Biology and Fundamental Medicine, Siberian Branch of the Russian Academy of Sciences, 8, Lavrentiev Ave., 630090 Novosibirsk, Russia.

出版信息

Molecules. 2020 Jul 31;25(15):3496. doi: 10.3390/molecules25153496.

Abstract

Two novel structural types of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors with hexahydroisobenzofuran and 3-oxabicyclo [3.3.1]nonane scaffolds were discovered. These monoterpene-derived compounds were synthesized through preliminary isomerization of (+)-3-carene to (+)-2-carene followed by reaction with heteroaromatic aldehydes. All the compounds inhibit the TDP1 enzyme at micro- and submicromolar levels, with the most potent compound having an IC value of 0.65 μM. TDP1 is an important DNA repair enzyme and a promising target for the development of new chemosensitizing agents. A panel of isogenic clones of the HEK293FT cell line knockout for the gene was created using the CRISPR-Cas9 system. Cytotoxic effects of topotecan (Tpc) and non-cytotoxic compounds of the new structures were investigated separately and jointly in the gene knockout cells. For two TDP1 inhibitors, and , a synergistic effect was observed with Tpc in the HEK293FT cells but was not found in TDP1 -/- cells. Thus, it is likely that the synergistic effect is caused by inhibition of TDP1. Synergy was also found for in other cancer cell lines. Thus, sensitizing cancer cells using a non-cytotoxic drug can enhance the efficacy of currently used pharmaceuticals and, concomitantly, reduce toxic side effects.

摘要

两种新型结构类型的酪氨酸-DNA 磷酸二酯酶 1(TDP1)抑制剂,具有六氢异苯并呋喃和 3-氧杂双环[3.3.1]壬烷骨架,被发现。这些单萜衍生化合物是通过(+)-3-蒈烯初步异构化为(+)-2-蒈烯,然后与杂芳基醛反应合成的。所有化合物在微摩尔和亚微摩尔水平上抑制 TDP1 酶,最有效的化合物的 IC 值为 0.65 μM。TDP1 是一种重要的 DNA 修复酶,是开发新型化学增敏剂的有前途的靶标。使用 CRISPR-Cas9 系统创建了一组基因敲除的 HEK293FT 细胞系同基因克隆。分别和联合研究了拓扑替康(Tpc)和新型结构的非细胞毒性化合物在基因敲除细胞中的细胞毒性作用。对于两种 TDP1 抑制剂和,在 HEK293FT 细胞中观察到与 Tpc 的协同作用,但在 TDP1 -/- 细胞中未发现。因此,协同作用可能是由 TDP1 的抑制引起的。在其他癌细胞系中也发现了与的协同作用。因此,使用非细胞毒性药物敏化癌细胞可以增强当前使用的药物的疗效,同时减少毒性副作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7a20/7436013/68602b78fe00/molecules-25-03496-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验